CorMedix Secures $150M in Convertible Debt for Major Acquisition
Deal News | Aug 12, 2025 | Goodwin
Moelis & Company has acted as the exclusive placement agent in CorMedix Inc.'s $150 million convertible debt offering, a strategic move to partly fund the latter's acquisition of Melinta Therapeutics LLC, valued at $300 million. This significant financial transaction was facilitated by Goodwin's Life Sciences team, who provided key advisory services to Moelis & Company. As a prominent global independent investment bank, Moelis & Company offers a wide range of strategic advisory services covering areas such as mergers and acquisitions, recapitalizations, restructurings, and capital market transactions across various industry sectors. The deal highlights Moelis & Company's role in facilitating major corporate transactions and CorMedix's strategy to enhance its positioning through strategic acquisitions.
Sectors
- Healthcare
- Financial Advisory
Geography
- United States – CorMedix Inc. and Melinta Therapeutics LLC are likely based in the United States, where the primary transaction is occurring.
- Global – Moelis & Company operates on a global scale, serving clients across different continents, including North and South America, Europe, the Middle East, and Asia-Pacific.
Industry
- Healthcare – Involves CorMedix Inc., which is acquiring Melinta Therapeutics LLC, both operating within the life sciences and healthcare sector.
- Financial Advisory – Moelis & Company provides financial advisory services, including this recent strategic capital raising and facilitation of a convertible debt deal.
Financials
- $150 Million – Amount raised in convertible debt to finance CorMedix Inc.'s acquisition.
- $300 Million – Value of the acquisition of Melinta Therapeutics LLC by CorMedix Inc.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| CorMedix Inc. | Target | Company | A life sciences company involved in the acquisition of Melinta Therapeutics LLC, facilitated by the issuance of $150 million in convertible debt. |
| Melinta Therapeutics LLC | Target | Company | Acquired by CorMedix Inc. in a transaction partially funded by convertible debt. |
| Moelis & Company LLC | Bidding Company/Buyer | Company | Served as the exclusive placement agent in the convertible debt financing for CorMedix Inc. |
| Goodwin | Legal Advisor | Company | Provided legal advisory services to Moelis & Company in the debt financing deal. |
| Ben Marsh | Advisor | Person | Part of the Goodwin team advising Moelis & Company. |
| Justin Platt | Advisor | Person | Part of the Goodwin team advising Moelis & Company. |
| Mac Taggart | Advisor | Person | Part of the Goodwin team advising Moelis & Company. |
| Jim Barri | Advisor | Person | Part of the Goodwin team advising Moelis & Company. |